Viking Long Fund GP LLC's Net Worth
$1.54 Billion
Who is Viking Long Fund GP LLC?
Viking Long Fund GP LLC has an estimated net worth of $1.54 Billion. This is based on reported shares across multiple companies, which include Wayfair Inc., FIRST DATA CORP, Adaptive Biotechnologies Corp, Editas Medicine, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., Urovant Sciences Ltd., Axovant Gene Therapies Ltd., and BridgeBio Pharma, Inc..
SEC CIK
Viking Long Fund GP LLC's CIK is 0001621607
Past Insider Trading and Trends
2019 was Viking Long Fund GP LLC's most active year for acquiring shares with 36 total transactions. Viking Long Fund GP LLC's most active month to acquire stocks was the month of January. 2016 was Viking Long Fund GP LLC's most active year for disposing of shares, totalling 9 transactions. Viking Long Fund GP LLC's most active month to dispose stocks was the month of May. 2019 saw Viking Long Fund GP LLC paying a total of $116,247,386.34 for 72,849,851 shares, this is the most they've acquired in one year. In 2020 Viking Long Fund GP LLC cashed out on 8,412,899 shares for a total of $302,143,539.29, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Editas Medicine, Inc. (EDIT) Snapshot price: $7.14
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 4
|
∞
| 5.46M |
—
|
—
| 5.46M |
Feb 8 - Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Arbutus Biopharma Corp (ABUS) Snapshot price: $2.5099
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Myovant Sciences Ltd. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +6.32% | 2.42M |
$8.25 | $19,999,996.50 | 40.77M |
Jun 4
| |||
Form 4
| +2.98% | 1.11M |
$20.27 | $22,500,004.05 | 38.34M |
Apr 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.58
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.23% | -1.00M |
$55.65 | -$55,650,000.00 | 29.99M |
Dec 14
| |||
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Urovant Sciences Ltd. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +0.08% | 18.2K |
$8.32 | $151,380.99 | 22.86M |
Scheduled
|
Jun 17 - Jun 19
| ||
Form 4
| +0.10% | 22.01K |
$8.06 | $177,300.64 | 22.84M |
Scheduled
|
Jun 12 - Jun 14
| ||
Form 4
| +0.09% | 21.34K |
$8.31 | $177,247.38 | 22.82M |
Scheduled
|
Jun 7 - Jun 11
| ||
Form 4
| +0.09% | 21.12K |
$7.86 | $165,950.15 | 22.8M |
Scheduled
|
Jun 4 - Jun 6
| ||
Form 4
| +0.08% | 17.75K |
$7.83 | $138,946.36 | 22.78M |
Scheduled
|
May 30 - Jun 3
| ||
Form 4
| +0.06% | 14.48K |
$7.63 | $110,461.18 | 22.76M |
Scheduled
|
May 24 - May 29
| ||
Form 4
| +0.09% | 19.83K |
$8.22 | $162,918.35 | 22.75M |
Scheduled
|
May 21 - May 23
| ||
Form 4
| +0.07% | 21.61K |
$7.63 | $162,884.29 | 31.35M |
May 16 - May 20
| |||
Form 4
| +13.38% | 2.68M |
$14.00 | $37,499,994.00 | 22.7M |
Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||